Whitepaper: Why extractables and leachables matter
Posted: 18 February 2021 | Nelson Laboratories LLC | No comments yet
Medicines and other healthcare products rely for their value, integrity and commercial longevity on a delicate balance between quality, safety and efficacy.
Medicines and other healthcare products rely for their value, integrity and commercial longevity on a delicate balance between quality, safety and efficacy. When that balance is disturbed by issues such as product adulteration, the damage to patients, revenues and corporate reputation can be substantial.
That is why the pharmaceutical and medtech industries, along with their associated regulators, are paying increasing attention to testing requirements for extractables and leachables (E&L). Recent trends in product development and manufacturing have multiplied the risks of unintended chemical changes that could compromise product integrity either during the manufacturing process or on the shelf.
Related content from this organisation
- Unmasking the unknown: how mass spectrometry delivers accurate identifications
- Review: Good identification practices for organic extractables and leachables via mass spectrometry
- On-demand webinar: Testing disinfectant agents for antimicrobial action on hard surfaces
- On-demand webinar: Key elements of a sterility assurance program
- Whitepaper: Why extractables and leachables matter
Related topics
Analytical techniques, Biologics, Biopharmaceuticals, Endotoxin, Formulation, Good Manufacturing Practice (GMP), Informatics, Ingredients, Manufacturing, Mass Spectrometry, Medical Devices, Outsourcing, Packaging, QA/QC, Regulation & Legislation, Research & Development (R&D), Supply Chain
